These results confirmed that RA synovial fluid enhanced NKCC1 activity, and the treatment of IL-6 antibody blocked the effects of RA synovial fluid on the modulation of NKCC activity and RVI in RA-FLS. The gene discussed is SLC12A2; the disease is rheumatoid arthritis.